Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of oral LTT462 in advanced MAPK pathway-altered solid tumors
NL-OMON46853Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rineterkib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), ovarian cancer and 1 more (5 arms), sponsored by Novartis. Primary endpoints: Safety, Dose-limiting toxicities and 1 more. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
rineterkib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)ovarian cancermelanoma
Beyond the preview
Go deeper on NL-OMON46853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46853.